Urothelial Cancer

Janaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

Ami Umesh Badami, MD, discusses the factors that guide treatment decision-making for patients with clear cell or non–clear cell renal cell carcinoma.

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

John K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.

John K. Lee, MD, PhD, discusses safety considerations for enfortumab vedotin in the treatment of metastatic urothelial cancer.